<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712452</url>
  </required_header>
  <id_info>
    <org_study_id>P070707</org_study_id>
    <nct_id>NCT00712452</nct_id>
  </id_info>
  <brief_title>Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve</brief_title>
  <acronym>IROCHIM</acronym>
  <official_title>Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the influence of chemotherapy, either for auto-immune disease,
      either for carcinologic disease, on clinical and biological markers of ovarian reserve, for
      young patients, with normal reproductive functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enrol patients between 18 and 35 years, treated with neoadjuvant or adjuvant
      chemotherapy for systemic lupus erythematosus (Group 1), breast cancer (Group 2) or Hodgkin
      disease (Group 3)to evaluate the clinical and biological markers of ovarian reserve. The
      follow-up will last 24 months for each patients with a visit before treatment, and at 3
      months, 6 months, one year and two years after treatment.

      During this period, we will collect pre and post treatment clinical data,and biological data
      and ultrasonographic data such as antral follicle count which is a marker of ovarian follicle
      reserve.These data were not observed in current practice.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    problems of insuffisant recruitment
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AMH level and antral follicle count</measure>
    <time_frame>one year after the chemotherapy treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMH level and antral follicle count at each visit</measure>
    <time_frame>3 months, 6 months, and two years after the chemotherapy treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal status (Estradiol, LH, FSH and progesterone levels)</measure>
    <time_frame>3 months, 6 months, and two years after the chemotherapy treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual cyclicity</measure>
    <time_frame>3 months, 6 months, and two years after the chemotherapy treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy</measure>
    <time_frame>3 months, 6 months, and two years after the chemotherapy treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infertility treatment if required</measure>
    <time_frame>3 months, 6 months, and two years after the chemotherapy treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>systemic lupus erythematosus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hodgkin disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biology and ultrasonography after chemotherapy</intervention_name>
    <description>Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biology and ultrasonography after chemotherapy</intervention_name>
    <description>Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>5FU, épirubicine, cyclephosphamide, taxanes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biology and ultrasonography after chemotherapy</intervention_name>
    <description>Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)</description>
    <arm_group_label>3</arm_group_label>
    <other_name>adriamycine, bléomycine, vinblastine, daunorubicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women volunteers treated by chemotherapy,

          -  ≥ 18 and ≤ 35 years old

          -  Regular menstrual cyclicity, between 25 and 35 days

          -  Social security affiliation

          -  Signed informed consent

        Exclusion Criteria:

          -  Women &lt; 18 and &gt; 35 years old

          -  Pregnancy

          -  Emergent treatment necessity

          -  No social security affiliation

          -  Virgin patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Fanchin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris Hôpital Antoine Béclère</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP-HP Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fertility</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

